Literature DB >> 24651009

PI3Kδ inhibition hits a sensitive spot in B cell malignancies.

Bart Vanhaesebroeck1, Asim Khwaja2.   

Abstract

A PI3Kδ-selective inhibitor shows impressive clinical activity in chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphomas. In these malignancies, the PI3K pathway is not mutationally activated as in many other cancers, but it is important for mediating supportive cues from the cancer microenvironment and the B cell antigen receptor.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24651009     DOI： 10.1016/j.ccr.2014.02.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  22 in total

Review 1.  Molecules in medicine mini-review: isoforms of PI3K in biology and disease.

Authors:  Bart Vanhaesebroeck; Maria A Whitehead; Roberto Piñeiro
Journal:  J Mol Med (Berl)       Date:  2015-12-10       Impact factor: 4.599

Review 2.  Current Treatment of Chronic Lymphocytic Leukemia.

Authors:  Krzysztof Jamroziak; Bartosz Puła; Jan Walewski
Journal:  Curr Treat Options Oncol       Date:  2017-01

3.  Phosphoinositide 3-kinase p110δ promotes lumen formation through the enhancement of apico-basal polarity and basal membrane organization.

Authors:  Juan Peng; Aline Awad; Sokhavuth Sar; Ola Hamze Komaiha; Romina Moyano; Amel Rayal; Didier Samuel; Annette Shewan; Bart Vanhaesebroeck; Keith Mostov; Ama Gassama-Diagne
Journal:  Nat Commun       Date:  2015-01-13       Impact factor: 14.919

4.  PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.

Authors:  Wenli Cui; Shutao Zheng; Xinxia Li; Yuqing Ma; Wei Sang; Ming Liu; Wei Zhang; Xiaoyan Zhou
Journal:  Tumour Biol       Date:  2016-07-22

Review 5.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 6.  Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).

Authors:  Valentina Sala; Jean Piero Margaria; Alessandra Murabito; Fulvio Morello; Alessandra Ghigo; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2017-06

7.  Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.

Authors:  Zhi Qi; Zihan Xu; Liuzhen Zhang; Yongkang Zou; Jinping Li; Wenyu Yan; Cheng Li; Ningshu Liu; Hong Wu
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

Review 8.  Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.

Authors:  Srinivasan Ramanathan; Feng Jin; Shringi Sharma; Brian P Kearney
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

9.  PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.

Authors:  Q Wang; P Liu; J M Spangle; T Von; T M Roberts; N U Lin; I E Krop; E P Winer; J J Zhao
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

10.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

Authors:  G S Choudhary; S Al-Harbi; S Mazumder; B T Hill; M R Smith; J Bodo; E D Hsi; A Almasan
Journal:  Cell Death Dis       Date:  2015-01-15       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.